Thorax, Vol 52, 1036-1039, Copyright © 1997 by Thorax.

Effects of airway calibre on lung delivery of nebulised salbutamol

BJ Lipworth and DJ Clark
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital & Medical School, University of Dundee, UK.

BACKGROUND: A study was undertaken to test the hypothesis that airway calibre may alter lung deposition and therefore lung bioavailability of inhaled drugs as a result of narrowed airways reducing peripheral drug delivery. This was evaluated using the early lung absorption profile of salbutamol over the first 30 minutes after inhalation. METHODS: Three groups were compared: (1) 10 normal subjects with mean forced expiratory volume in one second (FEV1) 109.5% predicted and mid forced expiratory flow (FEF25-75) 103.0%, (2) 10 mild asthmatic patients with FEV1 102.0% and FEF25-75 82.6%, and (3) 10 severe asthmatic patients with FEV1 49.2% and FEF25-75 27.5% predicted. Each subject had one study visit where a single dose of nebulised salbutamol was given (40 micrograms/kg) via a Ventstream nebuliser with mouthpiece followed by mouth rinsing. Plasma salbutamol levels were measured at five, 10, 20, and 30 minutes after the end of nebulisation with calculation of maximal (Cmax) and average (Cav) concentration over 0-30 minutes. Systemic beta 2 responses (plasma potassium, tremor and heart rate) and airway responses (FEV1, FEF25-75) were measured before and 30 minutes after nebulisation. RESULTS: For Cav over 0-30 minutes the severe asthmatic patients had a lower plasma salbutamol concentration (1.31 ng/ml) than either the normal subjects (2.40 ng/ml) or those with mild asthma (2.45 ng/ml): normal subjects versus severe asthmatics 95% CI 0.30 to 1.88, mild versus severe asthmatics 95% CI 0.07 to 2.21. Airway responses as delta FEF25-75 were lower in the severe asthmatic subjects (0.30 l/s) than in either the normal subjects (0.69 l/s) or those with mild asthma (0.74 l/s): normal subjects versus severe asthmatic subjects 95% CI 0.09 to 0.88, mild versus severe asthmatics 95% CI 0.04 to 0.93. Values for delta log tremor also showed attenuated responses in those with severe asthma (1.22 mg2/s) compared with normal subjects (2.00 mg2/s) or those with mild asthma (2.02 mg2/s): normal subjects versus those with severe asthma 95% CI -0.02 to 3.30, mild versus severe asthmatics 95% CI 0.02 to 3.30. CONCLUSIONS: These results show that baseline airway calibre significantly alters the early lung absorption profile of salbutamol in patients with severe asthma. This may have implications in terms of optimising dose and delivery of inhaled beta 2 agonists in these patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Burmeister Getz, E., Fisher, D. M., Fuller, R. (2009). Human Pharmacokinetics/Pharmacodynamics of an Interleukin-4 and Interleukin-13 Dual Antagonist in Asthma. J Clin Pharmacol 49: 1025-1036 [Abstract] [Full Text]  
• Nair, S., Thomas, E., Pearson, S. B., Henry, M. T. (2005). A Randomized Controlled Trial To Assess the Optimal Dose and Effect of Nebulized Albuterol in Acute Exacerbations of COPD. Chest 128: 48-54 [Abstract] [Full Text]  
• PEDERSEN, S. (2001). Do Inhaled Corticosteroids Inhibit Growth in Children?. Am. J. Respir. Crit. Care Med. 164: 521-535 [Full Text]  
• LIPWORTH, B J (2001). Revisiting interactions between hypoxaemia and {beta}2 agonists in asthma. Thorax 56: 506-507 [Full Text]  
• Ream, R. S., Loftis, L. L., Albers, G. M., Becker, B. A., Lynch, R. E., Mink, R. B. (2001). Efficacy of IV Theophylline in Children With Severe Status Asthmaticus. Chest 119: 1480-1488 [Abstract] [Full Text]  
• Fowler, S. J., Wilson, A. M., Griffiths, E. A., Lipworth, B. J. (2001). Comparative In Vivo Lung Delivery of Hydrofluoroalkane-Salbutamol Formulation Via Metered-Dose Inhaler Alone, With Plastic Spacer, or With Cardboard Tube. Chest 119: 1018-1020 [Abstract] [Full Text]  
• FOWLER, S. J, LIPWORTH, B. J (2000). Therapeutic equivalence of inhaled salbutamol. Thorax 55: 345e-345 [Full Text]  
• Lipworth, B. J. (1999). Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis. Arch Intern Med 159: 941-955 [Abstract] [Full Text]